Gujarat, IndiaAfter 24 weeks of treatment, all round hypoglycaemia decreased from 0.7 events/patientyear to 0.2 events/Table 1: All round demographic dataParameters Insulin na e Insulin users 206 113 (54.9) 93 (45.1) 57.three 68.three 26.three ten.2 11 9.1 ten.three 141 (68.4) 122 (59.two) All 812 502 (61.eight) 310 (38.two) 55.two 68.0 26.0 7.4 27 8.9 9.9 476 (58.6) 365 (45.0)Variety of participants 606 389 (64.two) Male N ( ) 217 (35.8) Female N ( ) Age (years) 54.5 Weight (kg) 67.9 25.9 BMI (kg/m2) Duration of DM (years) six.four No therapy 16 2 OGLD 16 HbA1c eight.9 FPG (mmol/L) 9.eight PPPG (mmol/L) Macrovascular 335 (55.3) complications, N ( ) Microvascular 243 (40.1) complications, N ( ) Prestudy therapy, N ( ) Insulin customers OGLD only No therapy Baseline therapy, N ( ) Insulin detemir GLD Insulin aspart GLD Basalinsulin aspart GLD Biphasic insulin aspart GLD Otherspatientyear in insulin na e group and from 1.8 events/patientyear to 0.three events/patientyear in insulin user group. The hypoglycaemia incidence in insulin naive group at 24 weeks was lower than that observed in insulin customers at baseline. SADRs which includes significant hypoglycaemic events didn’t take place in any from the study patients. Body weight and blood pressure decreased from baseline, while overall lipid profile and excellent of life enhanced at week 24 within the total cohort [Table 2 and 3]. Imply HbA1c and FPG values enhanced from baseline to study finish in the total cohort [Table 4].Biphasic insulin aspart OGLD206 (25.37) 590 (72.66) 16 (1.97) 89 (ten.96) 155 (19.09) 45 (5.54) 502 (61.82) 21 (two.59)Of the total cohort, 502 patients started on biphasic insulin aspart OGLD, of which 372 (74.1 ) were insulin na e and 130 (25.9 ) had been insulin customers. Following 24 weeks of remedy, hypoglycaemic events lowered for both insulin naive (from 0.9 events/patientyear to 0.3 events/ patientyear) and insulin user (from 1.four events/patientyear to 0.4 events/patientyear) groups. Physique weight decreased and top quality of life enhanced in the end of your study [Table five and 6]. Mean HbA1c and FPG values enhanced from baseline to study end in people who started on or have been switched to biphasic insulin aspart for both insulin na e and insulin user groups [Table 7].BMI: Body mass index, OGLD: Oral glucoselowering drug, HbA1c: Glycated hemoglobin A1c, FPG: Fasting plasma glucose, PPPG: Postprandial plasma glucose, DM: Diabetes mellitusTable 2: General safety dataParameter Hypoglycaemia (insulin na e), events/patientyear All Nocturnal Important Hypoglycaemia (insulin users), events/patientyear All Nocturnal Key Physique weight, kg Insulin na e Insulin users Lipids and BP (insulin na e) LDLC, mean (mmol/L), (N, 2.3,5-Dibromo-2-methylbenzoic acid Formula 5 mmol/L) HDLC, imply (mmol/L), (N, 1.(S)-H8-BINAP structure 0 mmol/L) TG, imply (mmol/L), (N, 2.PMID:22943596 three mmol/L) SBP, imply (mmHg), (N, 130 mmHg) Lipids and BP (insulin customers) LDLC, mean (mmol/L), (N, two.5 mmol/L) HDLC, imply (mmol/L), (N, 1.0 mmol/L) TG, imply (mmol/L), (N, 2.three mmol/L) SBP, mean (mmHg), (N, 130 mmHg) High quality of life, VAS scale (0100) Insulin na e Insulin customers N 606 Baseline 0.7 0.1 0.0 1.8 0.7 0.0 68.1 68.six three.9 (24, 9.0) 1.0 (140, 52.0) two.3 (124, 47.0) 135.five (184, 30.four) three.7 (7, 7.five ) 1.0 (48, 51.six) 2.2 (46, 50.0) 136.7 (55, 27.0) 56.8 57.1 Week 24 0.2 0.1 0.0 0.three 0.0 0.0 67.6 67.8 3.two (8, six.six) 1.1 (90, 74.4) 2.0 (103, 85.8) 123.1 (338, 77.2) 2.9 (7, 20.6 ) 1.1 (23, 67.six) 1.8 (30, 90.9) 123.five (118, 75.two) 87.1 88.2 Modify from baseline 0.5 0.0 0.0 1.five 0.7 0.0 0.5 0.eight 0.7 0.1 0.3 12.three 0.eight 0.1 0.4 13.2 30.2 31.436 157 268 269 264 606 93 93 92 204 430BP: Blood pressure,.